Dr Reddy’s Accuses Amarin Of ‘Illegally’ Blocking Vascepa API Supply
Indian Firm Has Sued Originator In A New Jersey Court
Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.
You may also be interested in...
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.